Search

Finding a treatment approach with high efficacy and minimal adverse reactions for advanced melanoma is still challenging. This study aimed to review and summarize available evidence regarding the effectiveness of the newly FDA-approved combination therapy of Relatmlimab and Nivolumab in patients with advanced melanoma and its comorbidities. We searched MEDLINE, EMBASE, and Cochrane Library for studies published in any language till 29/11/2023. We used the following Mesh and Emtree words, "melanoma" AND "relatlimab" AND "nivolumab". We screened 398 articles and included two single-arm clinical trials (N = 2) and one randomized clinical trial (RCT) (N = 1). In conclusion, The relatlimab/nivolumab combination therapy showed promising results for advanced melanoma patients. However, further research and longer follow-up periods are needed to compare it with previous treatments and validate its long-term effectiveness and safety., Competing Interests: Declarations. Competing interests: The authors declare no competing interests. Conflict of interest: The authors declare that they have no conflict of interest., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

Background: Recognition of sources in the brain and their interaction with mental fatigue states are interesting subjects for researchers., Objective: The aim of this study was to investigate the mental fatigue effects on brain areas by dynamic casual modeling (DCM) parameters that are extracted from event-related potential (ERP) signals which were then estimated based on mental fatigue data with visual stimulation., Methods: ERP were recorded based on a Continuous Performance Task in four consecutive trials. Active regions and brain sources were extracted by a Multiple Sparse Priors algorithm., Results: Four models are proposed for DCM. The parameters and the structure of the best model were obtained by SPM software for ERP in each of the four trials., Conclusion: The results illustrate that an increase of mental fatigue through trials leads to increased likelihood of choosing forward models.